Checkpoint Therapeutics, Inc. (CKPT): Stock Offering News

CKPT – Proposes to offer and sell shares of its common stock in an underwritten public offering; size not disclosed.


Key Facts Surrounding This News Item


  • CKPT had returned +44.33% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About Checkpoint Therapeutics, Inc. (CKPT)


Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. View our full CKPT ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

CKPT at a Glance

CKPT Current POWR Rating™
Overall POWR Rating™
CKPT Current Price $2.48 5.34%
More CKPT Ratings, Data, and News

CKPT Price Reaction

The day of this event (Mar. 7, 2018)
CKPT Closing Price$5.34 4.64%
CKPT Volume176,100
515.02% from avg
Leading up to this event
CKPT 1-mo return38.27%
After this event
CKPT 1-day return19.15%
CKPT 3-day return15.46%
CKPT 5-day return19.66%

CKPT Price Chart



More Checkpoint Therapeutics, Inc. (CKPT) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CKPT News
Page generated in 0.9956 seconds.